Circular Genomics and PharmatrophiX Join Forces to Propel Neurodegenerative Drug Development with circRNA Biomarkers

Strategic Partnership to Transform Neurodegenerative Therapies

On November 4, 2026, Circular Genomics, Inc. and PharmatrophiX, Inc. announced a strategic collaboration aimed at leveraging circular RNA (circRNA) biomarkers to advance the development of therapies for neurodegenerative diseases. This partnership marks a significant milestone in the quest for more effective treatments, particularly for Alzheimer’s disease, by utilizing innovative blood-based molecular profiling.

Circular Genomics is renowned for its precision neurology work and has developed a proprietary platform known as CircPath™, which specializes in circRNA profiling and analytics. PharmatrophiX, on the other hand, is a clinical-stage biopharmaceutical company dedicated to creating disease-modifying therapies aimed at neurodegenerative disorders.

Focus on Alzheimer’s Disease

The initial phase of the collaboration will focus on the study of LM11A-31, a pioneering small molecule targeting the p75 neurotrophin receptor (p75NTR). This drug is designed to protect brain cells and their connections by addressing the underlying mechanisms responsible for neurodegeneration. As part of a planned open-label study, Circular Genomics will apply its CircPath™ platform to analyze blood samples, aiming to track molecular changes over treatment duration and assess the efficacy of LM11A-31 in real time.

Paul Sargeant, PhD, President and CEO of Circular Genomics, stated, "The next generation of neurodegenerative drug development will require biomarkers that do more than measure disease burden—they must help us understand the biology changing in response to therapy." This collaboration allows Circular Genomics to showcase how circRNA biology can offer insights into patient heterogeneity and pharmacodynamic response, ultimately enhancing the clinical development landscape for complex neurological diseases.

Expanding Horizons

The collaboration aims not only to improve the understanding of Alzheimer’s treatment outcomes but also to explore its applicability to other conditions within PharmatrophiX's pipeline. Future applications may include studies on HIV-associated dementia, progressive supranuclear palsy (PSP), and additional neurotrophin-receptor programs. The two companies are also considering joint funding opportunities to support the ongoing translational biomarker research.

In addressing the potential of the collaboration, David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, highlighted the significance of integrating blood test insights into treatment progress assessments. "Understanding how the drug affects the processes in patients is central to our development strategy," he asserted, emphasizing the possible impact of their findings on future clinical trials for both LM11A-31 and other therapies targeting neurodegenerative disorders.

Conclusion

The partnership between Circular Genomics and PharmatrophiX represents a progressive step forward in the neuroscience field. By combining their respective expertise in molecular profiling and therapeutic development, they aim to redefine how neurodegenerative diseases are treated. This collaboration underscores the importance of innovations in biomarker discovery, which could ultimately lead to more effective and personalized therapeutic strategies for patients suffering from these challenging ailments.

For more information about Circular Genomics, visit circulargenomics.com. To learn more about PharmatrophiX and its pipeline, visit pharmatrophix.com.